Abstract
This paper is an overview on the place of IFN-alpha in metastatic renal cell carcinoma (MRCC). After a presentation of MRCC and the mode of action of IFN-alpha, the results of studies including IFN-alpha alone or in combination with IL-2, chemotherapy and other biological modifiers are presented. Finally, new trends for new drugs, including antiangiogenic therapies, are discussed.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antimetabolites, Antineoplastic / therapeutic use
-
Carcinoma, Renal Cell / blood supply
-
Carcinoma, Renal Cell / surgery
-
Carcinoma, Renal Cell / therapy*
-
Combined Modality Therapy
-
Fluorouracil / therapeutic use
-
Humans
-
Interferon-alpha / therapeutic use*
-
Interleukin-2 / therapeutic use
-
Kidney Neoplasms / blood supply
-
Kidney Neoplasms / surgery
-
Kidney Neoplasms / therapy*
-
Neoplasm Metastasis
-
Neovascularization, Pathologic / therapy
-
Randomized Controlled Trials as Topic
Substances
-
Angiogenesis Inhibitors
-
Antimetabolites, Antineoplastic
-
Interferon-alpha
-
Interleukin-2
-
Fluorouracil